Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hyperspectral imaging and robust statistics in non-melanoma skin cancer analysis.
Courtenay LA, González-Aguilera D, Lagüela S, Del Pozo S, Ruiz-Mendez C, Barbero-García I, Román-Curto C, Cañueto J, Santos-Durán C, Cardeñoso-Álvarez ME, Roncero-Riesco M, Hernandez-Lopez D, Guerrero-Sevilla D, Rodríguez-Gonzalvez P. Courtenay LA, et al. Among authors: del pozo s. Biomed Opt Express. 2021 Jul 20;12(8):5107-5127. doi: 10.1364/BOE.428143. eCollection 2021 Aug 1. Biomed Opt Express. 2021. PMID: 34513245 Free PMC article.
Near-infrared hyperspectral imaging and robust statistics for in vivo non-melanoma skin cancer and actinic keratosis characterisation.
Courtenay LA, Barbero-García I, Martínez-Lastras S, Del Pozo S, Corral de la Calle M, Garrido A, Guerrero-Sevilla D, Hernandez-Lopez D, González-Aguilera D. Courtenay LA, et al. Among authors: del pozo s. PLoS One. 2024 Apr 25;19(4):e0300400. doi: 10.1371/journal.pone.0300400. eCollection 2024. PLoS One. 2024. PMID: 38662718 Free PMC article.
Cognitive impairment and dementia in young onset Parkinson's disease.
Santos-García D, de Deus Fonticoba T, Cores Bartolomé C, Feal Painceiras MJ, García Díaz I, Íñiguez Alvarado MC, Paz JM, Jesús S, Cosgaya M, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Gómez Mayordomo V, Nogueira V, Dotor García-Soto J, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Mendoza Z, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Seijo M, Valero C, Alonso Redondo R, Buongiorno MT, Ordás C, Menéndez-González M, McAfee D, Martinez-Martin P, Mir P; COPPADIS Study Group. Santos-García D, et al. J Neurol. 2023 Dec;270(12):5793-5812. doi: 10.1007/s00415-023-11921-w. Epub 2023 Aug 14. J Neurol. 2023. PMID: 37578489
First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy.
Nieto A, Mazón Á, Nieto M, Ibáñez E, Jang DT, Calaforra S, Alba P, Pérez-Francés C, Llusar R, Montoro J, de Mateo A, Alamar R, El-Qutob D, Fernández J, Moral L, Toral T, Antón M, Andreu C, Ferrer Á, Flores IM, Cerdá N, Del Pozo S, Caballero R, Subiza JL, Casanovas M. Nieto A, et al. Among authors: del pozo s. Allergy. 2022 Oct;77(10):3096-3107. doi: 10.1111/all.15374. Epub 2022 May 27. Allergy. 2022. PMID: 35570712 Free PMC article. Clinical Trial.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
34 results